![Jason O’Byrne](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jason O’Byrne
Directeur Financier/CFO chez
VIR BIOTECHNOLOGY, INC.
Fortune : 384 469 $ au 30/06/2026
Profil
Jason V.
O’Byrne is Chief Financial Officer & Executive Vice President at Vir Biotechnology, Inc. since 2024.
Former roles include Chief Financial & Accounting Officer at Caribou Biosciences, Inc. from 2021 to 2024, Senior Vice President-Finance at Astellas Gene Therapies, Inc. from 2019 to 2021, Regional Controller at General Chemical Corp.
from 2002 to 2005, and Regional Head-Commercial Finance APAC at Genentech, Inc. Education includes an undergraduate degree from the University of British Columbia and an MBA from The Leonard N Stern School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VIR BIOTECHNOLOGY, INC. 0,02 % | 31/03/2026 | 37 730 ( 0,02 % ) | 384 469 $ | 30/06/2026 |
Postes actifs de Jason O’Byrne
| Sociétés | Poste | Début |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Directeur Financier/CFO | 02/10/2024 |
Anciens postes connus de Jason O’Byrne
| Sociétés | Poste | Fin |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Directeur Financier/CFO | 27/09/2024 |
| AUDENTES THERAPEUTICS, INC. | Directeur Financier/CFO | 01/02/2021 |
General Chemical Corp.
 General Chemical Corp. Industrial SpecialtiesProcess Industries Manufactures and supplies metal lubricant products | Corporate Officer/Principal | 01/01/2005 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
Formation de Jason O’Byrne
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
62
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Caribou Biosciences, Inc.
 Caribou Biosciences, Inc. BiotechnologyHealth Technology Develops technology-based solutions for cellular engineering and analysis | Health Technology |
University of British Columbia
 University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
General Chemical Corp.
General Chemical Corp. Industrial SpecialtiesProcess Industries Manufactures and supplies metal lubricant products | Process Industries |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes gene therapy products for patients with serious rare diseases | Health Technology |
The Leonard N Stern School of Business
 The Leonard N Stern School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vir Biotechnology, Inc.
 Vir Biotechnology, Inc. BiotechnologyHealth Technology Develops cures and treatments drug for viral & bacterial diseases | Health Technology |
